transplant
accept
treatment
modal
termin
organ
failur
therapi
use
prevent
reject
suppress
immun
system
result
transplant
recipi
often
high
risk
infect
prolong
frequent
exposur
healthcar
set
multipl
antibiot
may
predispos
transplant
recipi
colon
infect
multidrugresist
organ
use
good
infect
prevent
control
practic
extrem
import
throughout
continuum
care
solid
organ
transplant
sot
recipi
hospit
set
antimicrobialresist
pathogen
often
caus
infect
identifi
ed
admiss
discharg
result
increas
morbid
mortal
chapter
review
select
infect
prevent
control
practic
address
common
infect
transplant
recipi
us
center
diseas
control
prevent
cdc
issu
guidelin
prevent
infect
hematopoiet
stem
cell
transplant
hsct
recipi
specifi
calli
sot
recipi
pertin
guidelin
infect
prevent
control
issu
develop
cdc
healthcar
infect
control
practic
advisori
committe
hicpac
provid
specifi
c
recommend
pertin
patient
popul
guidelin
referenc
chapter
includ
guidelin
hand
hygien
healthcar
guidelin
prevent
healthcareassoci
pneumonia
guidelin
environment
infect
control
healthcar
facil
manag
multidrugresist
organ
healthcar
set
guidelin
isol
precaut
prevent
transmiss
infecti
agent
healthcar
set
guidelin
disinfect
steril
healthcar
facil
american
transplant
societi
publish
guidelin
manag
prevent
infect
organ
transplant
candid
recipi
address
specifi
c
aspect
infect
control
practic
pertin
transplant
societi
healthcar
epidemiolog
america
shea
infecti
diseas
societi
america
idsa
also
publish
compendium
strategi
prevent
healthcareassoci
infect
hai
acut
care
hospit
strategi
recent
revis
highlight
basic
prevent
practic
often
refer
bundl
guidanc
infect
control
program
regard
implement
practic
well
special
approach
infect
control
use
basic
infect
control
practic
despit
public
expert
guidanc
document
guidelin
issu
still
unresolv
author
chapter
describ
practic
institut
acknowledg
differ
approach
problem
might
exist
healthcareassoci
infect
caregiv
must
maintain
good
infect
prevent
practic
minim
transmiss
infect
healthcar
set
invas
devic
central
venou
cathet
cvc
indwel
urinari
cathet
ventil
expos
patient
addit
risk
infect
facil
implement
infect
prevent
bundl
design
prevent
deviceassoci
hai
due
success
seen
reduc
hai
center
medicar
medicaid
servic
cm
issu
new
guidelin
octob
hospit
longer
receiv
addit
payment
case
select
condit
present
admiss
includ
cvcassoci
bloodstream
infect
catheterassoci
urinari
tract
infect
mean
hospit
claim
paid
though
secondari
diagnosi
present
hospitalacquir
condit
hac
consid
never
event
may
still
problemat
transplant
recipi
care
attent
must
given
good
hand
hygien
practic
cvc
care
well
practic
decreas
risk
catheterassoci
urinari
tract
infect
protect
infect
prevent
control
issu
solid
organ
transplant
david
b
banach
maria
teresa
sevil
shimon
kusn
measur
patient
may
also
place
protect
precaut
heighten
awar
caregiv
potenti
seriou
infect
wherea
occup
safeti
health
administr
osha
bloodborn
pathogen
standard
focus
primarili
employe
protect
cdc
hicpac
publish
numer
patientfocus
guidelin
recommend
prevent
hai
revis
guidelin
isol
precaut
prevent
transmiss
infecti
agent
healthcar
set
updat
expand
guidelin
isol
precaut
hospit
transit
healthcar
deliveri
primarili
acut
care
hospit
healthcar
set
eg
home
care
ambulatori
care
freestand
specialti
care
site
longterm
care
creat
need
recommend
could
appli
healthcar
set
use
common
principl
infect
control
practic
could
modifi
ed
refl
ect
settingspecifi
c
need
revis
term
nosocomi
infect
replac
healthcareassoci
infect
better
refl
ect
chang
pattern
healthcar
deliveri
may
diffi
cult
determin
exact
site
exposur
infecti
agent
andor
acquisit
infect
patient
move
healthcar
deliveri
system
sar
experi
recent
experi
ebola
viru
diseas
highlight
need
better
prepar
new
emerg
pathogen
focus
way
minor
break
infect
control
techniqu
result
infect
transmit
healthcar
profession
section
guidelin
creat
evid
mount
environment
control
could
decreas
risk
fungal
infect
sever
immunocompromis
patient
protect
environ
pe
found
greatest
benefi
patient
undergo
allogen
hematopoiet
stem
cell
transplant
may
lesson
learn
success
implement
group
patient
organiz
characterist
eg
nurs
staffi
ng
level
composit
establish
safeti
cultur
also
identifi
ed
key
compon
promot
adher
recommend
infect
control
practic
combin
univers
precaut
bodi
substanc
isol
precaut
contact
human
blood
bodi
fl
uid
secret
excret
except
sweat
nonintact
skin
mucou
membran
contamin
item
requir
use
person
protect
equip
part
standard
precaut
respiratori
hygienecough
etiquett
safe
inject
practic
use
mask
insert
cathet
inject
materi
spinal
epidur
space
via
lumbar
punctur
procedur
ad
standard
precaut
transmissionbas
precaut
use
addit
standard
precaut
prevent
infect
spread
airborn
droplet
direct
contact
rout
certain
infect
requir
diseasespecifi
c
isol
precaut
includ
standard
precaut
airborn
precaut
use
patient
known
suspect
infect
agent
transmit
evapor
droplet
droplet
nuclei
mm
micron
remain
suspend
air
may
carri
away
infect
patient
measl
varicella
tuberculosi
primari
infect
includ
categori
patient
infect
must
hous
room
control
ventil
special
air
fi
lter
neg
pressur
room
prevent
infecti
droplet
nuclei
enter
gener
air
suppli
infect
other
certain
diseas
infl
uenza
adenoviru
gener
droplet
larger
mm
largers
particl
big
remain
suspend
air
therefor
special
ventil
requir
close
contact
respiratori
tract
secret
requir
diseas
transmiss
mask
worn
healthcar
worker
work
within
ft
infect
patient
prevent
inhal
infecti
droplet
contact
precaut
use
prevent
transmiss
certain
microorgan
may
found
patient
skin
inanim
object
patient
environ
includ
categori
epidemiolog
signifi
cant
organ
methicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococci
vre
clostridium
diffi
cile
respiratori
syncyti
viru
rsv
privat
room
recommend
patient
colon
infect
organ
may
cohort
togeth
necessari
neither
option
achiev
immunosuppress
state
potenti
roommat
evalu
exampl
place
vrecolon
patient
otherwis
healthi
broken
leg
would
prefer
place
patient
postop
transplant
recipi
might
becom
easili
colon
infect
contact
precaut
requir
glove
gown
worn
contact
patient
potenti
contamin
item
area
patient
room
likelihood
transmiss
patient
contact
cloth
remot
caregiv
like
touch
cloth
eg
lab
coat
pocket
thu
transmit
organ
hand
hicpaccdc
guidelin
manag
multidrugresist
organ
healthcar
set
recommend
don
gown
glove
upon
room
entri
discard
exit
room
patient
organ
implic
environment
transmiss
eg
vre
c
diffi
cile
norovirus
intestin
tract
agent
rsv
cdc
isol
techniqu
manual
defi
ned
protect
isol
categori
protect
neutropen
immunosuppress
patient
wherea
isol
categori
design
prevent
transmiss
diseas
infect
patient
other
purpos
protect
revers
isol
protect
highli
suscept
patient
neutropen
precaut
practic
design
reduc
microbi
contamin
patient
environ
mani
infect
immunosuppress
patient
attribut
patient
endogen
fl
ora
use
special
environment
precaut
recommend
except
allogen
stem
cell
transplant
recipi
protect
environ
necessari
minim
fungal
spore
count
environ
decreas
risk
invas
fungal
infect
reduc
risk
infect
nurs
care
often
focus
skin
integr
indwel
intraven
devic
good
oral
hygien
isol
precaut
select
organ
diseas
syndrom
present
sever
varieti
cathet
cuff
coat
impregn
antimicrobi
antisept
agent
reduc
risk
catheterrel
bacteremia
avail
shown
decreas
risk
clabsi
although
cathet
chlorhexidinesilv
sulfadiazin
coat
cathet
impregn
minocyclinerifampin
platinumsilv
silverco
cuff
may
provid
addit
protect
skin
fl
ora
costli
standard
cathet
recommend
clabsi
rate
could
control
use
basic
approach
use
antimicrobi
ointment
cathet
insert
site
longer
recommend
except
hemodialysi
cathet
insert
site
chlorhexidineimpregn
dress
may
benefi
cial
prevent
clabsi
daili
chlorhexidin
bath
may
also
reduc
rate
clabsi
intens
care
bone
marrow
transplant
unit
although
routin
replac
cathet
unnecessari
cvc
site
dilig
monitor
evid
infect
guidewir
use
cathet
exchang
local
red
tender
purul
materi
present
insert
site
employe
visitor
may
also
transmit
infect
transplant
recipi
healthcar
worker
undergo
evalu
health
histori
immun
statu
begin
employ
vaccin
healthcar
worker
histori
varicella
infect
seroneg
strongli
encourag
varicella
life
threaten
sot
recipi
staff
member
receiv
infl
uenza
vaccin
annual
alreadi
immun
hepat
b
receiv
hepat
b
vaccin
employ
healthcar
facil
welldefi
ned
polici
establish
potenti
infecti
personnel
patient
contact
employe
encourag
report
potenti
exposur
ill
human
resourc
polici
permit
temporari
reassign
furlough
duti
minim
potenti
exposur
transplant
recipi
communic
infect
pretransplant
screen
process
famili
member
educ
infect
prevent
strategi
receiv
annual
infl
uenza
vaccin
ensur
vaccin
date
order
better
protect
transplant
recipi
clinic
personnel
monitor
visitor
ill
cold
prevent
transmiss
poster
may
display
fl
u
season
addit
remind
despit
establish
defi
nition
criteria
determin
whether
pneumonia
acquir
hospit
set
one
diffi
cult
infect
infect
preventionist
classifi
cdc
three
specifi
c
defi
nition
nosocomi
pneumonia
defi
ned
incub
period
exist
fungal
pneumonia
suspect
tradit
onset
infect
hour
admiss
standard
separ
communityacquir
infect
hospitalacquir
infect
valid
isol
fungal
speci
expector
sputum
may
diagnost
clinician
often
start
antifung
therapi
encount
isol
could
also
repres
transient
colon
laboratori
contamin
necessarili
invas
diseas
therefor
compar
fungal
pneumonia
rate
among
hospit
diffi
cult
ubiquit
natur
circul
fungal
spore
gener
higher
spore
count
outdoor
determin
whether
discharg
patient
readmit
invas
fungal
pneumonia
acquir
infect
hospit
challeng
compar
data
incid
nosocomi
fungal
pneumonia
unavail
mani
institut
attempt
develop
defi
nition
hospitalassoci
fungal
pneumonia
tabl
detail
case
defi
nition
author
institut
arbitrari
hospit
day
prior
onset
infect
use
distinguish
hospitaland
communityacquir
fungal
infect
recent
review
construct
renovationrel
healthcareassoci
fungal
infect
show
decreas
number
outbreak
may
due
effect
infect
prevent
measur
high
number
previous
report
outbreak
healthcareassoci
aspergillosi
associ
follow
three
main
mechan
airborn
acquisit
typic
secondari
contamin
ventil
system
direct
contact
contamin
object
wound
dress
airborn
contact
mechan
may
implic
seen
sternal
fungal
osteomyel
sternotomi
hospit
water
system
may
potenti
reservoir
aspergillu
mold
aerosol
safe
level
bioaerosol
recogn
standard
frequenc
air
sampl
also
lack
rural
outdoor
air
concentr
fungi
may
high
colonyform
unit
per
cubic
meter
air
cfum
without
caus
pulmonari
infect
gener
popul
establish
safe
threshold
limit
indoor
environ
problemat
studi
establish
posit
correl
increas
airborn
spore
count
incid
invas
aspergillosi
research
collect
air
sampl
quantifi
number
airborn
spore
open
agar
plate
commonli
refer
settl
plate
use
estim
airborn
concentr
fungal
spore
number
spore
settl
agar
due
effect
graviti
presum
proport
airborn
concentr
reliabl
enough
routin
use
facil
perform
organ
transplant
settl
plate
howev
may
detect
fungi
aerosol
medic
procedur
eg
wound
dress
chang
describ
outbreak
aspergillosi
among
liver
transplant
patient
air
sampl
method
use
calibr
siev
impactor
centrifug
sampler
recommend
provid
standard
count
result
express
cfu
per
cubic
meter
routin
air
sampl
fungi
gener
recommend
construct
renov
time
isol
aspergillu
fungi
identifi
ed
patient
cultur
air
sampl
may
perform
assess
rel
level
spore
environ
outdoor
sampl
may
collect
appropri
control
fungal
coloni
type
found
indoor
sampl
outdoor
sampl
tenfold
log
reduct
indoor
count
due
airhandl
fi
ltration
indoor
sampl
predomin
particular
fungu
proport
outdoor
sampl
may
refl
ect
contamin
indoor
environ
cdc
guidelin
prevent
healthcareassoci
pneumonia
recommend
protect
environ
unit
allogen
hsct
recipi
unit
specifi
c
recommend
sot
recipi
howev
cdc
publish
guidelin
environment
infect
control
healthcar
facil
address
specifi
c
control
applic
patient
includ
recommend
specifi
c
organ
transplant
recipi
beyond
scope
review
detail
recommend
guidelin
sever
specifi
c
infect
type
discuss
facil
perform
sot
surgeri
minimum
conting
plan
case
disrupt
hvac
servic
special
design
isol
room
use
laminar
air
fl
ow
laf
andor
higheffi
cienci
particul
air
hepa
fi
ltration
may
provid
cleanest
air
possibl
hepa
fi
ltration
provid
minimum
air
chang
per
hour
often
reduc
fungal
spore
count
hepa
fi
lter
remov
particl
larger
mm
micron
hepa
fi
lter
may
instal
within
room
ventil
system
provid
highli
fi
ltere
posit
pressur
room
portabl
unit
may
place
patient
room
addit
air
fi
ltration
patient
room
tightli
seal
prevent
contamin
outdoor
sourc
door
remain
close
ensur
posit
pressur
reportedli
area
use
hepa
fi
ltration
posit
pressur
patient
room
fungal
spore
control
ventil
total
spore
count
less
cfum
aspergillu
count
less
cfum
room
design
focu
use
easytoclean
surfac
wall
horizont
surfac
smooth
nonpor
facilit
clean
prevent
entrap
bacteria
spore
porou
ceil
tile
carpet
fabric
window
treatment
shade
curtain
avoid
may
attract
dust
particl
new
design
avail
hous
curtain
shade
within
two
glass
panel
minim
dust
collect
still
provid
privaci
control
light
vinyl
plastic
blind
safe
frequent
clean
hospit
sot
recipi
travel
area
construct
renov
sever
immunocompromis
patient
requir
transport
protect
environ
wear
higheffi
cienci
respiratori
protect
mask
like
prevent
inhal
particul
transplant
recipi
also
avoid
dusti
construct
excav
landscap
site
discharg
histor
studi
report
associ
use
protect
isol
strategi
restrict
fresh
fruit
fl
ower
decreas
incid
infect
length
hospit
stay
declin
dramat
benefi
ts
protect
environ
reevalu
import
risk
factor
invas
aspergillosi
remain
patient
underli
immunosuppress
condit
highrisk
patient
may
develop
invas
aspergillosi
even
low
fungal
spore
count
construct
renov
hospit
often
associ
increas
number
case
aspergillosi
begin
renov
airborn
particul
fungal
spore
count
may
except
high
spore
dispers
environ
demolit
process
facil
guidelin
institut
publish
guidelin
design
construct
hospit
healthcar
facil
infect
control
personnel
involv
plan
stage
project
commiss
build
owner
requir
provid
infect
control
risk
assess
icra
determin
potenti
risk
transmiss
variou
infecti
agent
project
icra
conduct
panel
expertis
infect
control
epidemiolog
risk
manag
facil
design
construct
ventil
safeti
icra
conduct
earli
plan
phase
project
construct
begin
continu
project
construct
commiss
specifi
c
constructionrel
requir
mandat
icra
includ
contract
document
mani
state
health
depart
requir
icra
submiss
issu
permit
hospit
construct
renov
project
construct
renov
activ
plan
near
facil
handl
highrisk
transplant
recipi
even
strict
protect
guidelin
monitor
requir
may
establish
plan
process
guidelin
help
defi
ne
appropri
barrier
techniqu
prevent
spread
dust
debri
area
facil
construct
housekeep
personnel
train
danger
aspergillosi
emphasi
control
measur
strategi
prevent
nosocomi
aspergillosi
control
fungi
transmiss
dust
zygomycet
eg
mucor
rhizopu
speci
infect
control
intervent
prevent
nosocomi
aspergillosi
well
illustr
one
constructionassoci
outbreak
incid
invas
aspergillosi
rose
case
per
patientday
construct
period
control
measur
use
includ
portabl
hepa
fi
ltration
unit
instal
seal
window
easytoclean
tile
shade
increas
mainten
ventil
system
introduct
portabl
hepa
fi
lter
unit
import
step
undertak
institut
control
measur
infect
rate
decreas
case
per
patientday
construct
activ
outdoor
air
intak
ventil
system
may
becom
heavili
load
construct
dust
potenti
lead
increas
contamin
indoor
environ
increas
focu
fi
lter
mainten
import
success
contain
may
possibl
bone
marrow
transplant
unit
report
construct
vicin
maintain
construct
area
neg
pressur
establish
plastic
sheet
drywal
barrier
control
access
construct
zone
prevent
dust
contamin
patient
area
case
nosocomi
aspergillosi
suspect
crucial
look
facil
histori
aspergillosi
case
assess
background
rate
investig
ventil
defici
import
good
chanc
case
healthcareassoci
epidemiolog
investig
initi
effort
fi
nd
elimin
sourc
aspergillu
fl
avu
frequent
identifi
ed
report
constructionrel
contamin
indoor
environ
arnow
et
al
report
increas
spore
count
aspergillu
fumigatu
fl
avu
mean
cfum
associ
open
new
hospit
environment
assess
identifi
ed
fungal
contamin
carpet
fi
reproofi
ng
materi
ventil
fi
lter
fungi
may
contamin
damp
area
discolor
ceil
tile
peel
wallpap
studi
document
decreas
indoor
spore
count
institut
appropri
control
measur
sometim
air
sampl
recommend
assess
air
contamin
construct
hepa
fi
lter
chang
part
outbreak
investig
repeat
air
sampl
may
collect
identifi
ed
sourc
decontamin
remov
environment
audit
may
also
includ
period
sampl
role
fungal
type
investig
outbreak
unclear
multipl
fungal
strain
caus
healthcareassoci
infect
one
outbreak
given
ubiquit
presenc
fungi
environ
identifi
cation
differ
serial
aspergillu
strain
whole
genom
sequenc
within
singl
patient
may
limit
applic
epidemiolog
tool
aspergillu
speci
certainli
signifi
cant
fungal
pathogen
found
environ
fusarium
trichosporon
speci
dematiac
mold
zygomycet
normal
innocu
soil
plant
fungi
may
caus
infect
immunocompromis
patient
good
housekeep
practic
vital
highrisk
patient
area
area
visual
monitor
ensur
dust
contain
remov
patient
environ
nosocomi
infect
occur
within
institut
renov
ventil
system
provid
highli
fi
ltere
air
highrisk
patient
area
may
consid
although
antifung
prophylaxi
patient
may
use
case
may
still
occur
necessit
temporari
closur
contamin
patient
unit
suspens
transplant
activ
hospit
construct
project
research
univers
arkansa
medic
scienc
report
result
medlin
search
medic
literatur
publish
determin
number
hai
caus
waterborn
pathogen
fortythre
outbreak
report
includ
mani
nosocomi
outbreak
caus
pseudomona
aeruginosa
hai
attribut
use
contamin
water
includ
caus
legionella
pneumophila
p
aeruginosa
aeromona
acinetobact
burkholderia
enterobact
flavobacterium
pseudomona
speci
gondii
serratia
mycobacteria
aspergillu
speci
environment
protect
agenc
epa
publish
long
term
surfac
water
treatment
rule
rule
address
strategi
reduc
diseas
incid
associ
cryptosporidium
diseasecaus
microorgan
drink
water
individu
state
regul
code
may
identifi
requir
maintain
hot
water
temperatur
protect
patient
scald
temperatur
return
ideal
cold
water
temperatur
healthcar
facil
transplant
recipi
consid
increas
risk
develop
legionella
pneumonia
commonli
known
legionnair
diseas
even
process
water
treatment
plant
small
quantiti
aquat
bacteria
may
enter
home
build
may
live
biofi
lm
line
pipe
legionella
speci
multipli
warm
water
ideal
temperatur
rang
regul
concern
maximum
water
temperatur
design
prevent
scald
accid
often
fall
rang
increas
possibl
facil
becom
contamin
legionella
speci
sever
speci
nontubercul
mycobacteria
includ
mycobacterium
xenopi
tradit
believ
infect
caus
inhal
contamin
aerosol
gener
humidifi
er
aircondit
unit
cool
tower
shower
respiratori
tract
aspir
contamin
water
addit
mechan
transmiss
laboratoryconfi
rmed
legionellosi
patient
spent
day
continu
healthcar
facil
prior
onset
ill
consid
defi
nite
case
healthcareassoci
legionella
p
neumonia
occur
patient
spent
day
healthcar
facil
prior
onset
ill
consid
possibl
healthcareassoci
legionellosi
cdc
guidelin
prevent
nosocomi
pneumonia
discuss
issu
environment
monitor
control
recommend
state
facil
provid
routin
mainten
potabl
water
system
consid
use
steril
water
immunocompromis
patient
legionella
isol
water
reduc
incid
legionellosi
l
pneumophila
strain
may
virul
nonpneumophila
strain
advanc
molecular
fi
ngerprint
techniqu
instrument
associ
patient
isol
legionella
speci
cultur
facil
potabl
water
suppli
furthermor
lawsuit
success
link
nosocomi
infect
perceiv
facil
neglig
cultur
plumb
fi
xture
sink
spout
showerhead
ice
machin
drink
fountain
legionella
speci
identifi
potenti
sourc
bacteria
highrisk
patient
area
degre
contamin
percent
posit
fi
xture
quantiti
bacteria
present
vari
signifi
cantli
build
build
type
hot
water
system
water
temperatur
locat
build
age
play
role
colon
pipe
within
facil
monitor
control
legionella
speci
healthcar
facil
requir
team
effort
microbiolog
laboratori
infect
prevent
control
mainten
depart
must
work
togeth
provid
safe
environ
highrisk
patient
cdc
recommend
routin
environment
cultur
legionella
guidelin
state
could
compon
legionella
prevent
healthcar
facil
provid
care
transplant
recipi
may
appropri
identifi
sourc
infect
part
outbreak
investig
assess
effect
water
treatment
decontamin
protocol
guidelin
regard
cultur
frequenc
accept
level
posit
avail
gener
facil
establish
polici
environment
monitor
depend
patient
popul
environment
investig
identifi
sourc
legionella
recommend
outbreak
defi
ned
one
case
defi
nite
two
case
possibl
healthcareassoci
legionnair
diseas
within
period
rule
signifi
cant
quantiti
legionella
speci
isol
facil
control
measur
reduc
level
colon
institut
system
use
hold
tank
heater
allow
water
stagnat
bottom
tank
provid
reservoir
multipl
legionella
speci
immedi
control
legionella
set
outbreak
thermal
erad
superheat
fl
ush
hyperchlorin
water
suppli
recommend
ongo
control
legionella
could
done
use
coppersilv
ioniz
system
releas
low
concentr
metal
ion
water
distribut
system
ultraviolet
light
steril
mainten
elev
water
temperatur
chlorin
content
pointofus
fi
lter
found
effect
elimin
legionella
could
use
without
modifi
cation
disinfect
potabl
water
system
though
current
guidelin
transplant
unit
shower
head
tap
aerat
remov
clean
disinfect
monthli
use
chlorinebas
eparegist
product
dilut
bleach
may
use
eparegist
chlorin
disinfect
avail
addit
largevolum
room
air
humidifi
er
gener
aerosol
use
unless
subject
highlevel
disinfect
steril
water
use
even
control
mechan
place
healthcareassoci
legionellosi
may
occur
disrupt
water
distribut
system
water
main
break
use
fi
hydrant
fl
ood
intern
mainten
construct
disrupt
may
caus
chang
water
pressur
disrupt
biofi
lm
within
potabl
water
system
piec
biofi
lm
break
free
enter
water
suppli
water
may
appear
cloudi
dirti
local
water
author
may
issu
water
restrict
event
major
contamin
drink
water
suppli
establish
water
servic
disrupt
polici
help
protect
immunosuppress
patient
substitut
appropri
bottl
water
encourag
drink
mouth
care
ice
machin
fi
lter
may
becom
contamin
fi
lter
chang
restor
water
servic
suspend
shower
water
determin
safe
may
necessari
servic
restor
fi
xture
fl
ush
water
appear
clear
tub
bath
may
accept
littl
aerosol
water
occur
bath
process
bed
bath
system
gener
aerosol
recommend
american
societi
heat
refriger
aircondit
engin
ashra
standard
establish
minimum
risk
manag
requir
control
legionellosi
water
build
system
includ
inpati
healthcar
facil
interdisciplinari
design
team
author
respons
establish
implement
legionellosi
risk
manag
program
includ
limit
facil
staff
familiar
build
water
system
infect
prevent
control
staff
form
compon
program
includ
descript
potabl
nonpot
water
system
build
water
fl
ow
diagram
includ
water
sourc
water
treatment
system
control
measur
water
process
end
use
point
sink
shower
water
featur
ice
machin
identifi
cation
area
higher
probabl
infect
base
intend
water
use
vulner
infect
patient
area
identifi
cation
control
point
legionella
control
measur
put
place
establish
critic
limit
control
point
eg
temperatur
chlorin
level
establish
monitor
system
includ
mean
method
frequenc
monitor
physic
chemic
characterist
control
measur
ensur
within
critic
limit
verifi
cation
program
implement
valid
control
measur
effect
control
legionella
includ
determin
environment
cultur
legionella
perform
document
commun
plan
area
legionella
speci
identifi
ed
water
suppli
patient
reli
well
spring
water
encourag
water
suppli
check
one
mistaken
assumpt
bottl
water
safer
healthier
tap
water
howev
mani
water
product
process
reduc
bacteri
contamin
product
spring
water
emphas
natur
properti
may
actual
contain
bacteria
water
product
infect
caus
resist
organ
emerg
seriou
problem
hospit
world
due
part
increas
nonselect
use
broadspectrum
antibiot
agent
prophylaxi
treatment
indiscrimin
use
antibiot
reduc
normal
host
fl
ora
predispos
patient
colon
endem
multidrugresist
organ
c
diffi
cile
emerg
streptococcu
viridan
highli
resist
penicillin
associ
use
antibiot
neutropen
cancer
patient
center
routin
use
quinolon
prophylaxi
neutropen
patient
report
coagulaseneg
staphylococcu
gramneg
blood
isol
resist
agent
hai
resist
gramneg
organ
klebsiella
speci
stenotrophomona
maltophilia
burkholderia
cepacia
rise
trend
may
relat
use
broadspectrum
antibiot
gramneg
bacteria
produc
extendedspectrum
becom
increasingli
preval
pretranspl
broadspectrum
antibiot
use
associ
posttranspl
infect
caus
multidrugresist
organ
antimicrobi
stewardship
program
use
local
data
select
appropri
treatment
reduc
reservoir
multidrugresist
pathogen
within
medic
facil
reduc
inappropri
antibiot
use
prescrib
antibiot
like
benefi
cial
patient
minim
treatment
colon
use
broadspectrum
antibiot
judici
discontinu
unnecessari
lengthi
treatment
antimicrobi
essenc
antimicrobi
stewardship
cdc
launch
get
smart
healthcar
initi
guid
support
antimicrobi
stewardship
program
differ
set
order
improv
antibiot
prescrib
practic
patient
longer
inpati
stay
transplant
surgeri
may
becom
colon
multidrugresist
organ
chang
unit
network
organ
share
uno
alloc
algorithm
result
increas
durat
preoper
hospit
institut
data
demonstr
increas
number
case
mediastin
heart
transplant
caus
multidrugresist
pathogen
associ
increas
length
pretransplant
inpati
hospit
prior
transplant
activ
surveil
identifi
es
patient
colon
resist
bacteria
clinic
cultur
alon
strategi
use
control
rate
colon
infect
due
resist
bacteria
use
activ
surveil
mrsa
subsequ
decolon
mupirocin
shown
effect
reduc
infect
post
liver
transplant
though
data
demonstr
effect
wherea
cdc
guidelin
control
multidrugresist
organ
recommend
activ
surveil
mrsa
vre
approach
fail
control
transmiss
adequ
shea
guidelin
recommend
use
activ
surveil
identifi
patient
colon
mrsa
vre
among
highrisk
patient
state
mandat
screen
patient
mrsa
activ
surveil
mdr
gramneg
organ
includ
carbapenemresist
enterobacteriacea
cre
recommend
certain
highrisk
situat
order
prevent
spread
highli
resist
potenti
virul
organ
although
activ
surveil
done
routin
center
role
activ
surveil
cre
solid
organ
transplant
candid
recipi
unclear
area
worthi
futur
studi
enterococci
becom
signifi
cant
infect
control
problem
decad
evidenc
increas
nosocomi
infect
report
nni
compar
data
report
show
addit
increas
vre
infect
compar
januari
octob
enterococc
devicerel
healthcareacquir
infect
report
nhsn
caus
vre
enterococci
differ
streptococci
rel
resist
penicillin
cephalosporin
intrins
lowlevel
resist
aminoglycosid
lincosamid
antibiot
also
resist
bile
consid
normal
enter
fl
ora
adult
gener
exhibit
low
virul
may
isol
mouth
vagina
groin
anterior
urethra
target
vancomycin
cell
wall
alanyld
alanyl
vre
target
alter
low
affi
niti
vancomycin
use
molecular
type
techniqu
vre
strain
identifi
ed
compris
mainli
three
resist
phenotypesvan
van
b
van
c
van
phenotyp
plasmid
mediat
defi
nition
resist
high
level
vancomycin
teicoplanin
van
b
strain
exhibit
highlevel
resist
vancomycin
suscept
teicoplanin
class
c
show
constitut
lowlevel
resist
vancomycin
encount
enterococcu
gallinarum
enterococcu
casselifl
avu
epidemiolog
analysi
shown
enterococc
infect
often
origin
patient
colon
fl
ora
intraabdomin
cardiothorac
surgeri
manipul
urinari
tract
risk
factor
enterococc
infect
reportedli
sever
ill
one
main
risk
factor
develop
vre
bacteremia
critic
ill
patient
intens
care
unit
underli
medic
condit
includ
immunocompromis
patient
resid
oncolog
transplant
unit
also
increas
risk
colon
infect
vre
strain
increas
length
hospit
antibiot
use
contribut
patient
risk
although
vancomycin
use
predispos
factor
acquisit
organ
antimicrobi
agent
alter
normal
gramposit
anaerob
gut
fl
ora
may
allow
vre
fl
ourish
europ
glycopeptid
avoparcin
use
anim
feed
associ
vre
anim
human
antibiot
antianaerob
activ
shown
promot
vre
highdens
colon
anim
model
human
vancomycin
thirdgener
cephalosporin
reportedli
independ
associ
vre
preval
intens
care
unit
usa
report
demonstr
contact
spread
bacteria
patient
patient
directli
indirectli
via
hand
healthcar
worker
contamin
equip
environment
surfac
also
sourc
diseas
transmiss
set
solid
organ
transplant
vre
infect
occur
earli
posttranspl
period
strong
associ
antimicrobi
use
surgic
specif
biliari
complic
liver
transplant
recipi
develop
vre
bacteremia
compar
retrospect
transplant
recipi
develop
bacteremia
vancomycinsensit
enterococci
vse
vre
infect
associ
increas
episod
recurr
bacteremia
persist
isol
bacteria
origin
site
infect
whether
vre
strain
virul
vse
still
controversi
issu
studi
case
endovascular
infect
encount
among
vre
patient
none
among
vse
control
patient
vre
colon
rate
patient
await
liver
transplant
report
anoth
becam
colon
transplant
infect
vre
occur
patient
recent
metaanalysi
demonstr
posttranspl
mrsa
vre
colon
signifi
cantli
associ
posttranspl
mrsa
vre
infect
patient
colon
vre
either
transplant
longer
hospit
icu
stay
acquir
vre
transplant
also
higher
mortal
fecal
carriag
vre
also
studi
outbreak
renal
unit
author
use
restrict
enzym
analysi
ribotyp
show
outbreak
isol
clonal
relat
vre
isol
stool
renal
patient
ie
endstag
renal
diseas
patient
hospit
sampl
patient
commun
histori
hospit
antibiot
use
mani
studi
use
dna
analysi
show
nosocomi
transmiss
primari
rout
vre
colon
among
patient
cdc
hospit
infect
control
practic
advisori
committe
develop
guidelin
prevent
spread
vre
follow
four
main
point
crucial
prevent
prudent
vancomycin
use
educ
program
effect
microbiolog
laboratori
multidisciplinari
effort
control
organ
microbiolog
laboratori
initi
process
vre
control
promptli
accur
identifi
organ
vancomycin
resist
identifi
ed
routin
bacteri
suscept
test
polymeras
chain
reaction
pcr
test
use
primer
detect
vana
vanb
gene
vancomycinresist
strain
identifi
ed
infect
control
depart
patient
physician
unit
personnel
notifi
ed
patient
colon
infect
place
singl
room
may
cohort
vreposit
patient
bacteria
may
colon
intestin
tract
patient
poor
person
hygien
fecal
incontin
may
contamin
environ
bacteria
patient
may
also
contamin
immedi
environ
touch
surfac
bed
rail
nurs
call
button
televis
control
type
equip
may
adequ
disinfect
patient
leav
increas
risk
transmiss
next
patient
recommend
glove
gown
worn
one
enter
room
colon
patient
especi
endem
set
group
report
signific
decreas
vre
infect
vre
colon
institut
enhanc
infect
control
measur
conjunct
judici
restrict
certain
antibiot
vancomycin
thirdgener
cephalosporin
variou
report
document
isol
vre
strain
environment
surfac
noncrit
item
stethoscop
thermomet
use
patient
unless
thoroughli
disinfect
use
vre
patient
dedic
equip
prefer
may
share
among
cohort
patient
patient
may
screen
vre
carriag
collect
rectal
swab
stool
cultur
pcr
test
identifi
addit
case
inform
use
determin
transmiss
roommat
other
unit
infect
patient
identifi
ed
despit
institut
contact
precaut
carrier
incid
carriag
may
remain
vre
colon
may
persist
long
period
therefor
colon
infect
patient
may
requir
continu
isol
discharg
patient
transfer
anoth
facil
notifi
receiv
institut
patient
vre
statu
appropri
precaut
taken
imper
vreposit
patient
readmit
place
contact
isol
surveil
cultur
complet
concern
plasmid
carri
vancomycin
resist
gene
could
transmit
resist
gramposit
bacteria
particularli
aureu
exist
multipl
virul
factor
associ
pathogen
infect
would
potenti
life
threaten
organ
alreadi
resist
multipl
antimicrobi
agent
vancomycinresist
aureu
vrsa
isol
seven
case
vrsa
identifi
ed
usa
isol
vana
posit
patient
prior
histori
mrsa
enterococc
infect
colon
sever
underli
condit
receiv
vancomycin
prior
vrsa
infect
proper
isol
precaut
place
prevent
persontoperson
transmiss
seven
case
case
vrsa
identifi
ed
mrsa
wellrecogn
nosocomi
pathogen
caus
signifi
cant
infect
patient
popul
contact
precaut
use
isol
patient
mrsa
infect
colon
controversi
exist
use
mask
enter
mrsa
patient
room
patient
nasal
colon
may
spread
organ
surround
air
advoc
caregiv
mask
prevent
acquisit
organ
thu
minim
spread
patient
transmiss
hand
colon
staff
member
may
increas
touch
nose
patient
care
activ
templ
univers
experi
illustr
mrsa
colon
patient
like
infect
surgic
wound
research
french
studi
collect
surveil
cultur
liver
transplant
recipi
analysi
infect
data
found
mrsa
infect
occur
frequent
mrsa
carrier
patient
mrsa
noncarri
patient
p
among
liver
transplant
recipi
patient
underw
surgeri
within
prior
week
markedli
higher
risk
mrsa
infect
review
infect
occur
anoth
liver
transplant
center
usa
show
organ
recipi
becam
infect
mrsa
signifi
cant
increas
incid
preval
patient
infect
mrsa
time
primari
site
infect
vascular
cathet
wound
abdomen
lung
cmv
seroneg
p
primari
cmv
infect
signifi
cantli
associ
mrsa
infect
p
although
rel
uncommon
donorderiv
mrsa
transmiss
describ
follow
liver
transplant
qualiti
improv
program
aim
reduc
hamrsa
acquisit
infect
rate
multifactori
approach
toward
decreas
mrsa
transmiss
describ
collect
surveil
cultur
may
costeffect
patient
popul
highrisk
transplant
recipi
group
may
ideal
start
point
process
mrsa
control
program
involv
liver
transplant
patient
consist
activ
surveil
use
contact
precaut
cohort
colon
patient
treatment
intranas
mupirocin
time
transplant
educ
patient
visitor
import
hand
hygien
result
decreas
incid
new
mrsa
colon
mrsa
bacteremia
mrsa
infect
site
standard
defi
nition
multidrugresist
gramneg
bacteria
mdrgnb
includ
categori
bacteria
resist
multipl
class
antibiot
p
aeruginosa
acinetobact
baumanii
well
enterobacteriacea
eg
escherichia
coli
klebsiella
pneumonia
extendedspectrum
esbl
hydrolyz
antibiot
includ
extendedspectrum
cephalosporin
substanti
increas
mdrgnb
defi
ned
resist
three
antimicrobi
class
baumanii
frequent
resist
multipl
antibiot
includ
fl
uoroquinolon
aminoglycosid
becom
increasingli
resist
carbapenem
isol
resist
test
antibiot
report
patient
infect
due
mdrgnb
like
experi
delay
institut
effect
antimicrobi
therapi
higher
mortal
increas
cost
care
extendedspectrum
usual
found
k
pneumonia
k
oxytoca
e
coli
also
report
citrobact
enterobact
proteu
salmonella
serratia
gramneg
bacteria
gramneg
bacteria
esbl
typic
sensit
carbapenem
recommend
treatment
infect
due
organ
recent
k
pneumonia
carbapenem
hydrolyz
enzym
confer
resist
carbapenem
report
organ
caus
devic
surgeryassoci
hai
though
name
kpc
k
pneumonia
carbapenemas
initi
found
k
pneumonia
kpc
report
enterobacteriacea
includ
e
coli
enterobact
speci
serratia
variat
geograph
distribut
esblcontain
organ
occur
sporad
variou
state
k
pneumonia
kpc
becom
endem
eastern
unit
state
spread
throughout
usa
increas
infect
caus
carbapenemresist
enterobacteriacea
associ
high
mortal
rate
among
liver
transplant
recipi
resist
gene
gramneg
bacteria
could
chromosom
could
locat
mobil
genet
element
plasmid
transposon
transfer
differ
speci
gene
element
may
contain
multipl
gene
encod
resist
penicillin
cephalosporin
carbapenem
aminoglycosid
confer
multidrug
resist
quinolon
resist
usual
due
chromosom
mutat
usual
transfer
transfer
quinolon
resist
gene
encod
plasmid
identifi
ed
recent
mdrk
pneumonia
plasmid
contain
resist
determin
carbapenem
aminoglycosid
fl
uoroquinolon
report
risk
factor
colon
infect
mdrgnb
similar
mrsa
vre
includ
advanc
age
underli
diseas
sever
ill
transfer
patient
anoth
institut
particularli
nurs
home
prolong
hospit
gastrointestin
surgeri
transplant
presenc
invas
devic
cvc
exposur
antimicrobi
drug
prior
solid
organ
hematopoet
stem
cell
transplant
identifi
ed
risk
factor
infect
caus
carbapenemresist
k
pneumonia
bacteremia
due
enterobact
cloaca
pseudomona
putida
report
liver
transplant
recipi
autom
suscept
test
system
limit
detect
drug
resist
organ
provid
clinic
microbiolog
laboratori
familiar
organ
ensur
organ
test
use
method
provid
reliabl
suscept
result
hospit
outbreak
due
mdrgnb
report
similar
mrsa
vre
mani
patient
may
colon
infect
provid
unrecogn
reservoir
activ
surveil
screen
may
necessari
prevent
crosstransmiss
measur
control
spread
mdrgramneg
bacteria
similar
drugresist
organ
includ
administr
support
institut
automat
alert
provis
adequ
hand
hygien
facil
educ
personnel
regard
mdro
prevent
method
judici
antimicrobi
use
surveil
contact
precaut
numer
factor
may
caus
diarrhea
transplant
recipi
includ
immunosuppress
antibiot
enter
nutrit
agent
affect
bowel
motil
extend
use
antimicrobi
alter
bacteri
fl
ora
gut
provid
nich
multipl
c
diffi
cile
anaerob
sporeform
gramposit
rod
resist
mani
antimicrobi
agent
although
organ
occur
normal
enter
fl
ora
approxim
adult
may
also
caus
sever
gastroenter
manifest
either
diarrhea
coliti
c
diffi
cile
produc
follow
two
toxin
toxin
enterotoxin
toxin
b
cytotoxin
toxin
act
synergist
result
cellular
damag
hemorrhag
accumul
fl
uid
colon
patient
histori
antibiot
usag
onset
diarrhea
c
diffi
cile
common
caus
healthcareassoci
diarrhea
higher
rate
carriag
rang
report
hospit
patient
c
diffi
cile
associ
diarrhea
occur
sot
recipi
estim
case
c
diffi
cile
diseas
cdd
usa
result
death
one
specifi
c
strain
emerg
virul
resist
antibiot
particularli
fl
uoroquinolon
produc
toxin
toxin
b
produc
third
toxin
binari
toxin
diseas
sever
affect
patient
underli
risk
factor
cdd
outbreak
associ
fl
uoroquinolon
use
though
antimicrobi
also
implic
although
antibiot
agent
affect
normal
balanc
intestin
fl
ora
clindamycin
penicillin
fl
uoroquinolon
third
gener
cephalosporin
particularli
associ
develop
infect
factor
alter
gut
fl
ora
also
increas
risk
carriag
organ
bowel
diseas
use
stool
soften
antacid
associ
increas
carriag
diarrhea
also
associ
older
age
underli
diseas
enema
symptomat
patient
usual
risk
factor
certain
intrins
patient
factor
infl
uenc
rel
risk
develop
symptomat
infect
solid
organ
transplant
case
cdd
occur
fi
rst
month
transplant
like
attribut
increas
rate
hospit
use
antibiot
time
period
document
cluster
case
due
healthcareassoci
transmiss
frequent
associ
environment
contamin
bacteri
spore
one
studi
patient
initi
cultureneg
admit
gener
ward
acquir
c
diffi
cile
hospit
develop
diarrhea
author
abl
prove
transmiss
patient
use
immunoblot
techniqu
document
cluster
patient
room
two
occup
author
suggest
pattern
acquisit
situat
evid
transmiss
roommat
exist
one
cluster
investig
identifi
ed
two
case
strain
bacteria
restrict
endonucleas
test
strain
associ
abdomin
surgeri
perform
one
surgic
team
spore
product
organ
surviv
well
environ
c
diffi
cile
cultur
inanim
object
medic
instrument
toilet
bathroom
fl
oor
furnitur
bacteria
cultur
hand
medic
personnel
strain
isol
medic
staff
care
patient
c
diffi
cile
confi
rmed
patient
isol
patient
may
becom
colon
c
diffi
cile
via
transmiss
contact
patient
contamin
room
equip
medic
personnel
carri
bacteria
hand
environment
contamin
spore
occur
room
patient
cdd
asymptomat
carriag
nosocomi
attack
rate
vari
facil
facil
clinician
care
transplant
recipi
therefor
awar
nosocomi
transmiss
c
diffi
cile
real
possibl
earli
implement
infect
control
measur
may
prevent
occurr
case
detail
strategi
prevent
c
diffi
cile
hospit
set
publish
patient
place
privat
room
cohort
infect
patient
symptomat
patient
place
contact
precaut
healthcar
personnel
wear
glove
gown
enter
patient
room
patient
transport
outsid
unit
minim
patient
diarrhea
avoid
contamin
area
bacteri
spore
good
hand
hygien
essenti
soap
water
alcohol
hand
sanit
may
use
routin
endem
set
soap
water
prefer
outbreak
hyperendem
set
staff
member
must
observ
proper
procedur
visitor
encourag
wash
hand
thoroughli
leav
patient
room
dilut
hypochlorit
solut
product
epaapprov
claim
c
diffi
cile
activ
consid
unit
high
c
diffi
cile
rate
outbreak
environment
decontamin
isol
cohort
infect
patient
limit
clindamycin
signifi
cantli
reduc
cdd
use
dedic
patient
equip
dispos
rectal
thermomet
may
significantli
reduc
incid
cdd
acut
chronic
care
facil
use
whenev
possibl
although
initi
step
treatment
c
diffi
cile
discontinu
antibiot
agent
allow
recolon
gut
normal
fl
ora
oral
metronidazol
oral
vancomycin
often
use
treat
infect
random
doubleblind
placebocontrol
studi
show
patient
mild
moder
diseas
respond
compar
either
metronidazol
oral
vancomycin
patient
sever
diseas
howev
better
clinic
cure
vancomycin
vancomycin
consid
fi
rstline
agent
patient
sever
diseas
fecal
microbiota
transplant
emerg
promis
treatment
patient
frequent
relaps
cdad
howev
safeti
effi
caci
set
organ
transplant
unknown
guidelin
recommend
antimicrobi
prophylaxi
patient
risk
cdd
treatment
asymptomat
carriag
test
cure
cdd
report
follow
fulmin
cours
transplant
recipi
retrospect
studi
sever
cdd
show
lung
transplant
patient
fulmin
symptom
compar
patient
cdd
requir
colectomi
transplant
recipi
mostli
lung
transplant
though
actual
better
surviv
nontranspl
recipi
author
state
improv
awar
lower
threshold
surgeri
closer
followup
may
paradox
improv
outcom
transplant
recipi
review
cystic
fi
brosi
patient
show
lung
transplant
tend
complic
diseas
cours
studi
show
complic
diseas
relaps
rate
mortal
cdd
sot
recipi
overal
tb
incid
rate
usa
declin
tb
foreignborn
racialethn
minor
much
higher
compar
usborn
caucasian
proport
case
foreignborn
person
increas
account
case
report
mexico
philippin
india
vietnam
china
top
countri
origin
case
tb
foreignborn
patient
repres
reactiv
tb
acquir
countri
origin
author
treat
liver
transplant
recipi
activ
tb
import
risk
factor
birth
foreign
countri
endem
tb
multidrugresist
mdr
tb
defi
ned
resist
least
isoniazid
rifampin
appear
usa
worldwid
requir
treatment
secondlin
antitb
medic
usa
proport
patient
mdr
tb
without
previou
tb
remain
stabl
percentag
mdr
tb
remain
usborn
case
total
number
report
primari
mdr
tb
proport
occur
foreignborn
case
increas
account
primari
mdr
tb
us
case
cdc
world
health
organ
survey
laboratori
across
world
found
tb
isol
mdr
extens
drugresist
xdr
tb
provision
defi
nition
xdrtb
isol
resist
isoniazid
rifampin
least
three
six
main
class
secondlin
drug
definit
revis
octob
xdrtb
resist
isoniazid
rifampin
resist
fl
uoroquinolon
least
one
three
inject
secondlin
drug
amikacin
kanamycin
capreomycin
case
report
usa
occur
tb
preval
commun
presenc
mdrand
xdrtb
heighten
possibl
immunosuppress
individu
expos
case
activ
tb
transplant
recipi
suscept
infect
tuberculosi
speci
progress
activ
diseas
quit
rapid
similar
experi
patient
infect
hiv
april
three
patient
receiv
organ
usborn
man
histori
seizur
disord
alcohol
homeless
incarcer
initi
hospit
presum
aspir
pneumonia
two
kidney
recipi
develop
fever
week
transplant
cultur
grew
tuberculosi
match
donor
tuberculosi
isol
grew
csf
postmortem
transplant
unit
institut
appropri
isol
quickli
possibl
activ
tb
possibl
essenti
patient
increas
potenti
tb
place
isol
room
activ
diseas
even
remot
possibl
nosocomi
outbreak
tb
occur
among
renal
transplant
recipi
diseas
transmit
sourc
patient
fi
patient
unit
institut
airborn
precaut
delay
tb
infect
atyp
present
patient
restrict
fragment
length
polymorph
analysi
confi
rmed
strain
mortal
patient
group
shortest
incub
time
exposur
activ
infect
approxim
week
import
high
index
suspicion
tb
diseas
order
prevent
transmiss
prompt
placement
suspect
patient
airborn
infect
isol
aii
room
activ
tb
rule
airborn
precaut
discontinu
infecti
tb
consid
unlik
either
anoth
diagnosi
made
explain
patient
ill
sputum
specimen
collect
interv
least
one
collect
earli
morn
afb
smearneg
xpert
mtb
rif
assay
fdaapprov
nucleic
acid
assay
naa
detect
presenc
tb
rifampin
resist
sputum
specimen
neg
predict
valu
presenc
afb
smear
posit
tb
neg
assay
neg
assay
cdc
recommend
neg
sputum
specimen
prior
discontinu
airborn
precaut
patient
suspect
tb
allow
use
afb
smear
naa
combin
two
patient
tb
decis
regard
discontinu
aii
requir
neg
sputum
smear
clinic
criteria
cdc
guidelin
describ
ventil
system
requir
tb
isol
room
includ
engin
control
contain
droplet
nuclei
prevent
dissemin
outsid
patient
room
aii
room
must
neg
pressur
corridor
exhaust
air
must
vent
outsid
build
fi
ltere
hepa
fi
lter
recircul
aii
room
perman
instal
visual
mechan
monitor
pressur
differenti
room
corridor
occupi
patient
suspect
confi
rmed
tb
ultraviolet
germicid
irradi
devic
instal
irradi
air
conduit
bacteria
inactiv
equal
six
air
chang
per
hour
new
renov
healthcar
facil
construct
aii
room
equal
air
chang
per
hour
facil
may
replac
retrofi
ventil
system
fulfi
safeti
criteria
ventil
design
also
requir
varicella
isol
employe
must
use
nation
institut
occup
safeti
health
niosh
approv
fi
ttest
respir
power
airpurifi
respir
enter
room
patient
activ
suspect
tb
activ
infect
transplant
recipi
may
present
tradit
symptom
found
gener
popul
pulmonari
infi
ltrate
pleural
effus
may
constitut
tb
infect
without
typic
symptom
mani
transplant
candid
termin
organ
failur
anerg
transplant
recipi
remain
becom
anerg
secondari
immunosuppress
agent
administ
prevent
organ
reject
therefor
use
tuberculin
skin
test
tst
monitor
transplant
recipi
rare
provid
use
inform
import
inform
provid
convers
neg
posit
tuberculin
skin
test
occur
neg
result
rule
infect
furthermor
valu
anergi
test
question
longer
recommend
done
routin
even
patient
react
one
antigen
tst
test
neg
patient
may
still
latent
infect
even
activ
tb
dissemin
tb
occur
frequent
transplant
recipi
major
host
defens
tb
cellmedi
immun
tst
test
close
famili
member
may
provid
addit
inform
patient
potenti
spread
infect
recent
year
vitro
interferon
gamma
releas
assay
igra
becam
avail
diagnosi
latent
tb
quantiferon
tb
test
qiagen
germani
tspottb
test
oxford
immunotec
uk
test
measur
product
lymphocyt
incub
synthet
peptid
simul
protein
present
mtb
test
specifi
c
tst
detect
mtb
infect
much
less
fals
posit
result
relat
previou
bcg
administr
previou
exposur
atyp
mycobacteria
test
approv
us
food
drug
administr
cdc
recommend
use
test
indic
tst
fluoresc
microscopi
evalu
acidfast
bacillu
afb
smear
radiometr
cultur
method
provid
import
diagnost
inform
may
lead
earlier
initi
discontinu
patient
isol
mani
microbiolog
laboratori
use
rapid
test
method
detect
confi
rm
tb
includ
nucleic
acid
amplifi
cation
test
detect
mtb
smearposit
smearneg
respiratori
specimen
dna
probe
speci
identifi
cation
transplant
recipi
expos
person
activ
tb
contact
investig
initi
recent
tst
igra
result
chest
radiograph
taken
exposur
may
use
baselin
data
addit
tst
test
perform
week
exposur
evalu
skin
test
convers
prophylact
isoniazid
inh
therapi
consid
prevent
diseas
exposur
consid
signifi
cant
sourc
patient
strain
tb
either
document
suspect
drug
resist
use
altern
prophylact
regimen
consid
prophylact
regimen
multidrugresist
tb
well
establish
past
author
use
pyrazinamid
levofl
oxacin
exposur
occur
among
organ
transplant
recipi
regimen
associ
high
rate
discontinu
medic
due
advers
drug
effect
intern
debat
regard
use
bcg
vaccin
prevent
tb
spread
ongo
usa
indic
use
rare
exist
dissemin
bcg
diseas
risk
immunocompromis
patient
includ
transplant
recipi
june
cdc
american
thorac
societi
at
formul
new
recommend
regard
tb
prophylaxi
introduc
two
term
fi
rst
term
target
tuberculin
test
ie
tb
test
tst
placement
patient
high
risk
develop
tb
second
term
latent
tb
infect
ie
patient
infect
tb
develop
tb
diseas
chemoprophylaxi
prevent
therapi
term
treatment
latent
tb
infect
skin
indur
mm
tst
test
consid
posit
follow
patient
categori
patient
infect
hiv
patient
receiv
immunosuppress
agent
includ
transplant
recipi
patient
recent
contact
activ
tb
patient
abnorm
chest
radiograph
consist
old
tb
patient
high
risk
candid
treatment
latent
tb
three
regimen
treatment
latent
tb
infect
exist
follow
inh
month
rifampin
month
inh
rifapentin
week
inh
rifapentin
conveni
long
halflif
rifapentin
allow
weekli
dose
cdc
recommend
directli
observ
treatment
regimen
clinician
note
howev
regimen
could
risk
use
sot
recipi
case
sever
inh
hepat
report
sever
liver
injuri
result
death
fi
patient
occur
result
rifampinpyrazinamid
combin
longer
recommend
rifampin
also
associ
sever
reject
solid
organ
due
interact
cyclosporin
tacrolimu
varicella
highli
infecti
viru
seroneg
household
contact
may
becom
infect
infect
famili
infect
control
manag
vzv
immunosuppress
popul
involv
diffi
cult
issu
varicella
transmit
via
airborn
rout
primari
infect
chickenpox
viru
particl
releas
airway
patient
environ
transmiss
may
also
occur
direct
contact
moist
vesicl
transmiss
viru
usual
start
day
prior
rash
onset
last
skin
lesion
crust
cdc
guidelin
requir
airborn
contact
precaut
patient
varicella
dissemin
zoster
one
diffi
cult
task
infect
control
defi
ne
dissemin
zoster
institut
room
isol
local
dermatom
zoster
transmiss
occur
primarili
direct
contact
skin
lesion
standard
precaut
necessari
immunosuppress
host
even
small
number
moist
lesion
possibl
respiratori
secret
may
contain
enough
viral
particl
transmit
infect
suscept
individu
airborn
rout
shed
viral
particl
skin
lesion
surround
air
adult
cadaver
renal
transplant
recipi
occupi
privat
room
adjac
patient
zoster
develop
fatal
hepat
nosocomi
transmiss
primari
varicella
infect
use
pcr
sawyer
et
al
confi
rmed
vzv
dna
air
sampl
collect
varicella
patient
room
air
sampl
collect
zoster
patient
room
sampl
viru
detect
outsid
door
neg
pressur
isol
room
although
may
repres
failur
ventil
system
maintain
neg
pressur
room
staff
member
leav
door
room
open
obvious
aerosol
viral
particl
occur
viru
also
detect
day
onset
rash
use
techniqu
varicella
infect
suscept
immunosuppress
patient
may
result
viscer
diseas
associ
high
mortal
seri
three
adult
liver
transplant
recipi
develop
varicella
hepat
one
patient
die
develop
adult
respiratori
distress
syndrom
dissemin
intravascular
coagul
introduct
vaccin
signifi
cantli
reduc
varicellazost
morbid
mortal
use
expand
sinc
includ
hivinfect
children
percentag
adult
count
least
two
vaccin
current
avail
varivax
singleantigen
varicella
vaccin
proquad
combin
varicella
mmr
vaccin
latter
contain
viru
former
vaccin
varicella
vaccin
contraind
transplant
recipi
made
live
attenu
viru
howev
experi
leukem
children
shown
vaccin
safe
effect
report
also
demonstr
live
attenu
vaccin
safe
effi
caciou
suscept
pediatr
kidney
transplant
recipi
research
studi
administ
vaccin
candidaci
result
show
reduc
incid
varicella
transplant
also
report
vaccin
transplant
one
seroconvers
occur
children
requir
multipl
dose
minor
local
skin
reaction
observ
risk
healthi
individu
develop
rash
vaccin
transmit
immunosuppress
patient
low
therefor
vaccin
suscept
individu
includ
healthcar
worker
live
household
transplant
recipi
contraind
vaccin
manufactur
recommend
healthcar
worker
develop
vesicl
care
suscept
individu
although
hypothes
vaccin
strain
viru
may
capabl
caus
secondari
infect
case
document
gener
consensu
benefi
ts
vaccin
household
contact
immunocompromis
individu
outweigh
low
risk
transmiss
vaccin
viru
transplant
recipi
varicella
vaccin
also
use
healthi
person
postexposur
prevent
measur
mostli
unvaccin
children
ideal
within
day
exposur
transplant
coordin
must
frequent
evalu
exposur
transplant
recipi
individu
possibl
chickenpox
commonli
exposur
occur
contact
famili
member
usual
child
defi
ning
natur
exposur
durat
proxim
diseas
progress
import
step
assess
process
direct
exposur
one
occur
facetofac
indoor
durat
signifi
cant
exposur
clear
expert
say
exposur
min
signifi
cant
though
other
state
hour
need
document
concern
patient
varicellazost
immun
statu
must
easili
access
adult
patient
seroposit
vzv
even
recal
chickenpox
exposur
patient
vzv
infect
cdc
advisori
committe
immun
practic
acip
current
recommend
varizig
administr
consid
seroneg
immunocompromis
patient
certain
group
pregnant
women
newborn
complic
diseas
could
life
threaten
varizig
expect
provid
maximum
benefi
administ
soon
possibl
exposur
although
effect
administ
within
day
exposur
although
breakthrough
infect
varicellazost
immunoglobulin
vzig
administr
common
use
amelior
sever
diseas
one
studi
sot
pediatr
popul
receiv
vzig
median
age
year
develop
varicella
develop
sever
diseas
usual
dosag
unit
kg
weight
maximum
unit
anoth
exposur
occur
week
administr
vzig
dose
addit
dose
vzig
administ
provid
continu
passiv
immun
patient
get
monthli
highdos
ivig
mgkg
protect
last
dose
given
less
week
exposur
varicella
immun
globulin
could
prolong
incub
period
week
patient
given
varizig
monitor
sign
symptom
varicella
day
exposur
antivir
therapi
start
soon
sign
symptom
varicella
occur
acyclovir
may
also
prevent
attenu
infect
vzv
exposur
may
constitut
valid
altern
especi
case
come
medic
attent
day
exposur
author
advoc
use
vzig
case
lifethreaten
vzv
infect
possibl
children
renal
diseas
receiv
steroid
acyclovir
fda
approv
treatment
varicella
healthi
children
american
academi
pediatr
aap
recommend
consider
acyclovir
treatment
individu
risk
moder
sever
varicella
valu
acyclovir
prophylact
agent
immunocompromis
host
unclear
varizig
recommend
exposur
individu
vzv
limit
data
support
use
acyclovir
postexposur
prophylaxi
healthi
children
though
expert
support
approach
immunocompromis
patient
particularli
varizig
unavail
suscept
healthcar
worker
report
exposur
vzv
develop
chickenpox
one
report
incid
varicella
exposur
approach
suscept
healthcar
worker
report
exposur
furlough
work
day
exposur
base
averag
incub
period
day
knowledg
transmiss
may
occur
day
day
onset
rash
suscept
healthcar
worker
expos
vzv
put
transplant
recipi
risk
furlough
absenc
also
cost
implic
caus
disrupt
patient
care
therefor
cdc
recommend
vaccin
suscept
healthcar
worker
contraind
identifi
ed
healthcar
worker
receiv
acyclovir
prophylaxi
may
exhibit
longer
incub
period
develop
rash
maintain
accur
record
employe
data
concern
vaccin
previou
histori
chickenpox
import
suscept
employe
activ
encourag
receiv
varicella
vaccin
respiratori
tract
viral
infect
season
preval
children
adult
transmit
droplet
rather
aerosol
cough
sneez
talk
may
gener
droplet
usual
project
farther
ft
sourc
patient
special
ventil
requir
inpati
isol
hospit
set
suction
respiratori
secret
perform
bronchoscopi
may
also
gener
droplet
common
respiratori
viral
infect
includ
rsv
infl
uenza
parainfl
uenza
adenoviru
infect
control
aspect
respiratori
viral
infect
similar
rsv
describ
exampl
recent
year
import
virus
sot
recipi
receiv
recognit
realiz
virus
caus
signifi
cant
morbid
viral
infect
could
follow
superinfect
bacteri
pathogen
lead
bacteri
pneumonia
also
associ
acut
chronic
reject
particularli
lung
transplant
recent
year
introduct
sensit
molecular
techniqu
clinic
diagnosi
respiratori
virus
allow
earli
detect
virus
also
put
emphasi
virus
like
rhinoviru
metapneumoviru
overview
respiratori
syncyti
viru
rsv
rna
viru
caus
upper
lower
respiratori
tract
infect
usual
year
age
reinfect
common
healthi
host
selflimit
gener
mild
outbreak
commun
usual
occur
season
peak
late
spring
autumn
last
winter
variabl
onset
infect
year
year
well
variou
region
usa
exampl
florida
rsv
season
come
earlier
last
longer
viru
may
spread
nurseri
caus
sever
respiratori
infect
infant
underli
medic
condit
bronchopulmonari
dysplasia
congenit
heart
diseas
prematur
viral
shed
usual
last
week
period
may
longer
infant
younger
month
age
pneumonia
nosocomi
infect
often
parallel
outbreak
commun
rsv
surviv
dri
stay
viabl
hour
surfac
fomit
includ
glove
transmiss
occur
direct
contact
person
shed
viru
form
droplet
contact
contamin
hand
handkerchief
eat
utensil
articl
viral
particl
may
inocul
eye
nasal
mucosa
touch
area
contamin
hand
therefor
nosocomi
outbreak
may
occur
patient
patient
also
caregiv
visitor
cold
immunocompromis
patient
may
develop
lower
tract
lung
infect
pneumonia
rsv
may
infect
sot
recipi
recent
year
case
report
pediatr
sot
popul
also
adult
present
respiratori
symptom
two
liver
transplant
recipi
younger
month
age
intub
symptom
began
soon
transplant
later
die
rsv
pneumonia
may
suggest
direct
inocul
viru
lower
respiratori
tract
bypass
upper
airway
ribavirin
administ
oral
intraven
may
reduc
morbid
mortal
due
rsv
infl
uenza
b
parainfl
uenza
nevertheless
routin
use
recommend
possibl
toxic
expos
healthcar
provid
inhal
form
ongo
debat
regard
defi
nitiv
benefi
cial
effect
vaccin
avail
rsv
prevent
palivizumab
human
murin
antirsv
monoclon
antibodi
given
monthli
im
inject
begin
prior
continu
rsv
season
typic
novemb
april
northern
hemispher
prophylaxi
infant
children
risk
sever
rsv
infect
survey
pediatr
solid
organ
transplant
center
usa
almost
respond
center
use
palivizumab
prophylaxi
infect
control
measur
promptli
institut
prevent
nosocomi
transmiss
contact
precaut
use
infant
young
children
immunosuppress
individu
glove
gown
use
enter
room
patient
rsv
parainfl
uenza
adenoviru
prevent
contact
respiratori
secret
mask
eye
protect
necessari
procedur
gener
vapor
respiratori
secret
expect
outbreak
cohort
symptomat
patient
emphas
hand
hygien
may
reduc
transmiss
other
success
cohort
requir
earli
diagnosi
rsv
epidem
start
commun
shell
vial
cultur
rapid
antigen
detect
immunofl
uoresc
assay
ifa
enzymelink
immunosorb
assay
elisa
greatli
acceler
diagnosi
compar
viral
isol
techniqu
recent
institut
use
pcr
diagnosi
respiratori
virus
molecular
techniqu
sensit
respiratori
viral
infect
usual
manifest
selflimit
upper
respiratori
tract
ill
may
result
potenti
lifethreaten
lower
respiratori
infect
immunocompromis
patient
univers
pittsburgh
medic
center
infl
uenza
preval
among
lung
transplant
recipi
among
organ
recipi
secondari
bacteri
pneumonia
occur
patient
infl
uenza
complic
occur
three
patient
includ
myocard
myositi
bronchiol
obliteran
report
transplant
recipi
receiv
infl
uenza
vaccin
develop
infl
uenza
despit
vaccin
publish
due
suboptim
respons
transplant
recipi
protein
vaccin
rais
question
use
antivir
chemoprophylaxi
futur
april
infl
uenza
pandem
report
solid
organ
transplant
recipi
develop
pneumonia
admit
icu
die
organ
recipi
famili
healthcar
provid
must
realiz
import
receiv
annual
inactiv
infl
uenza
vaccin
reduc
risk
diseas
transmiss
cdc
advisori
committe
immun
practic
acip
hicpac
recommend
us
healthcar
worker
get
annual
infl
uenza
vaccin
live
attenu
infl
uenza
vaccin
laiv
administ
nasal
spray
recommend
immunocompromis
patient
may
given
close
contact
immunosuppress
individu
though
person
care
patient
protect
environ
avoid
contact
patient
least
day
receipt
laiv
parainfl
uenza
adenovirus
may
also
caus
lifethreaten
infect
may
also
spread
nosocomi
rapid
identifi
cation
respiratori
virus
especi
pediatr
ward
help
cohort
staff
patient
epidem
recogn
commun
viral
gastroenter
usual
selflimit
syndrom
healthi
host
sever
virus
associ
gastroenter
includ
rotaviru
noroviru
enter
adenoviru
calicivirus
enter
coronaviru
astroviru
rotavirus
norovirus
epidemiolog
signifi
cant
agent
gastroenter
virus
caus
endem
epidem
diseas
throughout
world
particular
rotavirus
associ
outbreak
children
develop
countri
associ
high
mortal
rate
symptom
often
includ
vomit
diarrhea
dehydr
fever
may
present
dehydr
may
sever
enough
requir
hospit
intraven
fl
uid
replac
incub
period
rang
day
symptom
usual
last
less
week
transmiss
rotaviru
occur
fecalor
rout
maximum
viral
shed
stool
occur
day
onset
diarrhea
nosocomi
infect
associ
insuffi
cient
use
appropri
infect
control
measur
rotaviru
infect
repres
case
nosocomi
diarrhea
children
associ
rotaviru
gastroenter
reject
small
bowel
allograft
may
relat
decreas
immunosuppress
agent
due
diarrhea
usa
infect
occur
children
age
month
matern
antibodi
protect
wane
infect
occur
frequent
octob
april
usual
viru
produc
selflimit
diarrhea
howev
prematur
infant
transplant
recipi
may
develop
sever
diseas
although
rotavirus
gener
caus
bloodi
stool
fecal
occult
blood
loss
report
pediatr
liver
transplant
recipi
rotavirus
remain
viabl
water
dri
inanim
object
hand
mani
day
investig
day
care
center
rotaviru
outbreak
demonstr
viru
pcr
toy
environment
surfac
rotaviru
may
transmit
patient
aerosol
contamin
inanim
object
occur
fece
also
aerosol
gener
bedpan
clean
patienttopati
transmiss
may
result
miniepidem
within
hospit
adult
contact
patient
rotaviru
may
exhibit
subclin
ill
infect
control
measur
institut
promptli
whenev
patient
incontin
develop
diarrhea
standard
precaut
adequ
unless
patient
incontin
diaper
contact
precaut
ad
case
good
hand
hygien
essenti
glove
gown
usag
patient
contact
fecal
contamin
like
clean
room
surfac
eparegist
hospit
disinfect
adequ
clean
surfac
patient
room
institut
infect
control
measur
interrupt
outbreak
pediatr
oncolog
ward
presum
occur
contamin
toy
includ
contact
precaut
daili
clean
playroom
dilut
bleach
solut
fi
rst
rotaviru
vaccin
approv
usa
rotashield
wyethlederl
vaccin
pediatr
taken
market
year
later
associ
intussuscept
februari
new
vaccin
rotateq
merck
co
licens
usa
oral
live
vaccin
develop
human
bovin
viru
associ
intussuscept
given
three
dose
month
complet
administr
week
age
second
vaccin
rotarix
glaxcosmithklin
licens
april
live
attenu
oral
vaccin
given
infant
two
dose
month
infant
two
vaccin
equival
although
origin
studi
shown
associ
postlicensur
studi
demonstr
low
risk
intussuscept
certain
popul
support
use
vaccin
univers
novemb
may
delay
onset
reduc
rate
rotaviru
infect
observ
attribut
introduct
rotaviru
vaccin
data
avail
regard
safeti
effi
caci
vaccin
immunosuppress
infant
believ
infant
live
household
immunosuppress
patient
still
vaccin
despit
small
risk
transmiss
vaccin
rotaviru
good
infect
prevent
control
practic
essenti
protect
highli
suscept
transplant
recipi
qualiti
manag
patient
safeti
initi
becom
drive
forc
provid
better
patient
outcom
insur
interest
infect
data
identifi
program
superior
patient
result
process
improv
initi
balanc
evalu
costeffect
although
prevent
measur
laf
highli
effect
may
costli
routin
use
provid
addit
benefi
patient
scientist
valid
use
new
strategi
renew
focu
best
practic
includ
basic
concept
hand
hygien
clean
disinfect
prevent
infect
essenti
